AR Naylor a, J.-B. Ricco a, GJ de Borst a, S. Debus a, J. de Haro a, A. Halliday a, G.
Hamilton a, J. Kakisis a, S. Kakkos a, S. Lepidi a, HS Markus a, DJ McCabe a, J. Roy a, H …

Background Patients with peripheral artery disease have an increased risk of cardiovascular
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications …

Stroke is a heterogeneous syndrome, and determining risk factors and treatment depends
on the specific pathogenesis of stroke. Risk factors for stroke can be categorized as …

Although cardiologists have long treated patients with coronary artery disease (CAD) and
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …

Recurrent stroke affects 9% to 15% of people within 1 year. This European Stroke
Organisation (ESO) guideline provides evidence-based recommendations on …

2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …

The European Society of Vascular Medicine (ESVM) was founded in Paris in 2012 as a
confederation of already existing and emerging European societies of vascular medicine. At …

Background The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises
the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein …

The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …

Abstract Purpose of Review: Death from stroke has decreased over the past decade, with
stroke now the fifth leading cause of death in the United States. In addition, the incidence of …